Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Maker Of Hepatitis Drugs Goes Crazy After Merck Agrees To Buy The Company For $3.85 Billion

Myles UdlandJun 9, 2014, 18:07 IST

REUTERS/David McNew

Shares of Idenix Pharmaceuticals are up more than 230% after announcing Merck will buy the company for $3.85 billion.

The deal values Idenix $24.50 per share; shares of Idenix closed at $7.23 on Friday.

Idenix is engaged in the development of hepatitis C drugs, and according to the merger announcement, Idenix has three hepatitis C drugs in clinical development.

Gilead Sciences, which has seen shares gain more than 120% since the beginning of 2013, received FDA approval for its hepatitis C drug Sovaldi in December. Shares of Gilead are down about 1.5% in pre-market trading.

Merck and Idenix expect the deal to close in the third quarter. In pre-market trading Merck is down 0.7%.